Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $889K | $837K | $3.00M | — | $10.0M | $3.00M | $1.41M | $3.50M | — | $5.82M |
| Revenue growth | — | -5.8% | 258.2% | — | — | -70.0% | -52.9% | 147.5% | — | — |
| Operating income | -$23.9M | -$27.8M | -$58.2M | -$77.1M | -$81.4M | -$89.8M | -$50.9M | -$47.1M | -$64.2M | -$89.4M |
| Operating margin | -2686.3% | -3325.7% | -1940.2% | — | -814.2% | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Net income | -$21.9M | -$27.3M | -$56.7M | -$76.3M | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.2M |
| Net margin | -2460.4% | -3263.9% | -1890.3% | — | -842.3% | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (diluted) | -$0.64 | -$0.66 | -$1.19 | -$1.51 | -$0.91 | -$0.86 | -$5.53 | -$2.53 | -$1.55 | $1.01 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.0M | -$22.7M | -$39.1M | -$62.8M | -$35.0M | -$65.7M | -$43.5M | -$37.0M | -$56.0M | -$76.3M |
| Capital expenditures | $519K | $860K | $9.24M | $6.31M | $1.34M | $4.15M | $130K | $331K | $2.45M | $7.97M |
| Free cash flow | -$13.5M | -$23.5M | -$48.4M | -$69.1M | -$36.4M | -$69.8M | -$43.6M | -$37.3M | -$58.5M | -$84.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $69.1M | $138M | $18.8M | $129M | $12.6M | $32.9M | $14.2M | $14.5M | $23.4M | $78.4M |
| Total assets | $111M | $179M | $174M | $223M | $151M | $79.6M | $64.2M | $64.0M | $109M | $220M |
| Total liabilities | $12.0M | $8.67M | $40.4M | $45.0M | $48.6M | $37.2M | $37.5M | $49.2M | $64.9M | $60.4M |
| Long-term debt | — | — | — | — | — | — | — | — | $13.0M | $7.81M |
| Shareholders' equity | $99.1M | $170M | $134M | $178M | $103M | $42.4M | $26.8M | $14.8M | $44.0M | $159M |
| Retained earnings | -$332M | -$360M | $2.60M | -$486M | -$571M | -$656M | -$695M | -$750M | -$813M | -$742M |
| Shares (wtd avg diluted) | 34.2M | 46.9M | 47.9M | 83.6M | 96.1M | 3.94M | 7.86M | 21.4M | 41.0M | 66.1M |
Every figure is extracted from ABEONA THERAPEUTICS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.